Antibe Therapeutics

Antibe Therapeutics A publicly traded biotechnology company [ATE.TO; ATBPF] commercializing a breakthrough advance in the treatment of inflammation. Our drug pipeline addresses large markets in non-addictive management of chronic and post-surgical pain.

Antibe Therapeutics is a publicly traded biotechnology company commercializing a breakthrough advance in the treatment of inflammation. Antibe’s lead drug, now in late Phase 2 trials, is demonstrating unprecedented safety in the treatment of chronic pain, a condition that affects more than 50 million Americans alone. Our second pipeline drug is intended to replace a range of opioids in treating po

Antibe Therapeutics is a publicly traded biotechnology company commercializing a breakthrough advance in the treatment of inflammation. Antibe’s lead drug, now in late Phase 2 trials, is demonstrating unprecedented safety in the treatment of chronic pain, a condition that affects more than 50 million Americans alone. Our second pipeline drug is intended to replace a range of opioids in treating po

Operating as usual

We just released an update on otenaproxesul and our expanded pipeline following a full scientific and strategic review i...
10/14/2021
Antibe Therapeutics Provides Update on Otenaproxesul and Expanded Drug Pipeline – Antibe Therapeutics

We just released an update on otenaproxesul and our expanded pipeline following a full scientific and strategic review involving external experts and key opinion leaders. The key findings are:

• Lead drug, otenaproxesul, ideally suited for US$13 billion post-operative pain market
• Targets urgent need to reduce opioid prescriptions, with shorter path to market envisaged
• Label expansion strategy potentially includes migraine, dysmenorrhea and dental pain
• Enlarged pipeline addresses significant unmet medical needs, additional IP protection expected
• Chronic pain program investigating alternative treatment regimens
• Strong balance sheet fully funds multiple parallel clinical development programs

“In our comprehensive review, it became apparent that otenaproxesul’s remarkable potency, GI protection and overall safety profile should be leveraged for acute pain use,” commented Dan Legault, Antibe’s CEO. “Short-term pain management has its own considerable challenges, not the least being a continued reliance on opioids, for which otenaproxesul is an ideal fit. Building on commercial research already in hand, we are initially targeting post-operative pain, with a plan to add further acute pain indications over time. Importantly, given the relatively short trials required, we foresee a faster path to market than originally envisaged with our chronic pain program. We are also pursuing a new indication with high unmet need for ATB-352, harmonizing its development with otenaproxesul’s new acute pain program.”

Read the full release at antibethera.com/news/antibe-therapeutics-provides-update-on-otenaproxesul-and-expanded-drug-pipeline

TORONTO, CANADA — (October 14, 2021) – Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies for a wide range of inflammatory conditions, is pleased to provide an update following a full sci...

On Thursday, August 12th at 9:00 am ET, join Dan Legault, our CEO, and Dr. Joseph Stauffer, our Chief Medical Officer, a...
08/09/2021
Canaccord Genuity 41st Annual Growth Conference

On Thursday, August 12th at 9:00 am ET, join Dan Legault, our CEO, and Dr. Joseph Stauffer, our Chief Medical Officer, at the Canaccord Genuity 41st Annual Growth Conference for the latest on Antibe’s opportunity, capability and strategy wsw.com/webcast/canaccord60/ate.to/2745292.

We provided a clinical update for otenaproxesul today: antibethera.com/news/antibe-therapeutics-provides-clinical-update...
08/03/2021
Antibe Therapeutics Provides Clinical Update for Otenaproxesul – Antibe

We provided a clinical update for otenaproxesul today: antibethera.com/news/antibe-therapeutics-provides-clinical-update-for-otenaproxesul

– Current AME study paused in adherence to safety protocol TORONTO, CANADA — (August 3, 2021) – Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, has placed its absor...

We just released an update to our shareholders:Our achievements in the last twelve months have set the stage for a promi...
07/27/2021
Antibe Therapeutics Provides July 2021 Corporate Update – Antibe

We just released an update to our shareholders:

Our achievements in the last twelve months have set the stage for a promising year ahead. With a cash position that provides more than two years of runway and fully funds the initial Phase III trial, we are adding value through comprehensive clinical development, ongoing partnering engagement and multi-pronged intellectual property (“IP”) advancement.

Read on at antibethera.com/news/antibe-therapeutics-provides-july-2021-corporate-update

– Phase III preparations proceeding well; AME study underway – New IP in development to expand indications and bolster existing pipeline – Potential listing on senior U.S. exchange synchronized with first Phase III trial TORONTO, CANADA – (July 27, 2021) To our shareholders, Our achievements...

With our lead drug candidate targeting #pain from #osteoarthritis, here's ten excellent tips for people travelling with ...
07/20/2021
10 Tips for Pain-Free Travel With Osteoarthritis

With our lead drug candidate targeting #pain from #osteoarthritis, here's ten excellent tips for people travelling with that condition healthcentral.com/slideshow/pain-free-travel-tips-with-osteoarthritis

Here are some tips to feeling good from head to toe, whether you’re traveling by plane, train or car.

Today we filed our financial and operating results for the fiscal year ended March 31, 2021.“Since the beginning of the ...
06/28/2021
Antibe Therapeutics Reports 2021 Year-End Results and Business Highlights – Antibe

Today we filed our financial and operating results for the fiscal year ended March 31, 2021.

“Since the beginning of the year we’ve made significant progress,” commented Dan Legault, Antibe’s CEO. “Our Phase III preparations for otenaproxesul achieved several milestones, including the clearance of its IND application with the FDA in the United States. While we continue to navigate COVID-19 restrictions, we’re pleased to launch our required AME study next week which will also inform the dose selection for the Phase III adaptive trial. The successful amalgamation with Antibe Holdings provides a unified intellectual property base and strengthens our position with potential partners. On that front, our ability to execute deals was highlighted by the US$100 million partnership with Nuance Pharma in China, and we’re now entering confidential discussions for the large markets.”

antibethera.com/news/antibe-therapeutics-reports-2021-year-end-results-and-business-highlights

– Phase III-enabling activities for otenaproxesul proceeding well; AME study begins next week – Ended year with a strong $72 million cash position, providing over two years of runway and fully funding Phase III adaptive trial TORONTO, CANADA — (June 28, 2021) – Antibe Therapeutics Inc. (TSX:...

We're pleased to announce a strategic collaboration with Dalriada Drug Discovery to develop new drug candidates and fort...
06/25/2021
Antibe Therapeutics Collaborates with Dalriada Drug Discovery to Accelerate Pipeline Expansion – Antibe

We're pleased to announce a strategic collaboration with Dalriada Drug Discovery to develop new drug candidates and fortify our intellectual property position for our current pipeline.

“The robust data from otenaproxesul’s extensive animal studies and human trials have highlighted the broad therapeutic and commercial potential of our drug platform,” commented Dan Legault, Antibe’s CEO. “As we prepare for otenaproxesul’s Phase III program, our strong balance sheet also enables us to tap Dalriada’s scientific expertise and throughput capacity to further our pipeline expansion strategy and IP position – efficiently and cost-effectively. This collaboration also leverages the projects already underway with our U.S. university-based chemistry group.”

antibethera.com/news/antibe-therapeutics-collaborates-with-dalriada-drug-discovery-to-accelerate-pipeline-expansion

– Enables rapid advancement of multiple drug discovery programs to exploit hydrogen sulfide platform in new disease areas TORONTO, CANADA — (June 25, 2021) – Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its unique hydrogen sulfide platform to develop n...

ICYMI: Could #inflammation be the cause of myriad chronic conditions? harvardmagazine.com/2019/05/inflammation-disease-d...
06/17/2021
Raw and Red-Hot

ICYMI: Could #inflammation be the cause of myriad chronic conditions? harvardmagazine.com/2019/05/inflammation-disease-diet

Could inflammation be the cause of myriad chronic conditions?

"Patients with #osteoarthritis are at increased risk for developing Parkinson's disease ... it is now recognized that #i...
06/15/2021
Osteoarthritis: A Link With Parkinson's?

"Patients with #osteoarthritis are at increased risk for developing Parkinson's disease ... it is now recognized that #inflammation plays a major role in the development of osteoarthritis, while neuroinflammation is characteristic of Parkinson's disease." medpagetoday.com/rheumatology/arthritis/92998 #TargetingInflammation

Inflammation may contribute to both joint and nerve degeneration

We're pleased to announce that we'll be participating in the following investor conferences in June:2021 LD Micro Invita...
06/07/2021

We're pleased to announce that we'll be participating in the following investor conferences in June:

2021 LD Micro Invitational XI:
Live company presentation by Scott Curtis, our Executive VP, and Dr. Joseph Stauffer, our Chief Medical Officer, on Wednesday, June 9, 2021 at 12:30 pm (Eastern Time). https://ldmicrojune2021.mysequire.com/

Raymond James Human Health Innovation Conference:
Live company presentation by Dan Legault, our CEO, and Dr. Joseph Stauffer on Wednesday, June 23, 2021 at 8:40 am (Eastern Time). https://kvgo.com/rj-health/antibe-therapeutics-inc-june-2021

antibethera.com/news/antibe-therapeutics-to-present-at-upcoming-virtual-investor-conferences-2

DYK about the impact of #chronicpain?  In the U.S. alone, the number of people experiencing chronic pain exceeds those a...
06/04/2021
Pain Trends Among American Adults, 2002–2018: Patterns, Disparities, and Correlates | Demography | Duke University Press

DYK about the impact of #chronicpain? In the U.S. alone, the number of people experiencing chronic pain exceeds those affected by heart disease, cancer, and diabetes combined. In 2012, the annual economic cost of pain in the U.S. was estimated at more than $600 billion and has likely increased since then. For individuals, chronic pain is a key determinant of quality of life, healthcare utilization and disability. Moreover, pain and pain treatments are linked to the unprecedented upsurge of #opioid-related overdoses and deaths among American adults—a public health crisis in its own right https://read.dukeupress.edu/demography/article/58/2/711/168526/Pain-Trends-Among-American-Adults-2002-2018

Anna Zajacova, Hanna Grol-Prokopczyk, Zachary Zimmer; Pain Trends Among American Adults, 2002–2018: Patterns, Disparities, and Correlates. Demography 1 April 2021; 58 (2): 711–738. doi: https://doi.org/10.1215/00703370-8977691

Congratulations to our founder and Chief Scientific Officer, Dr. John L. Wallace and his colleagues for their paper in F...
05/31/2021
Gaseous Mediators as a Key Molecular Targets for the Development of Gastrointestinal-Safe Anti-Inflammatory Pharmacology

Congratulations to our founder and Chief Scientific Officer, Dr. John L. Wallace and his colleagues for their paper in Frontiers in Pharmacology, providing an overview of the gaseous mediators-based NSAIDs along with their mechanisms of action, with special emphasis on possible implications for gastrointestinal mucosal defense mechanisms frontiersin.org/articles/10.3389/fphar.2021.657457/full

Non-steroidal anti-inflammatory drugs (NSAIDs) represent one of the most widely used classes of drugs and play a pivotal role in the therapy of numerous inflammatory diseases. However, the adverse effects of these drugs, especially when applied chronically, frequently affect gastrointestinal (GI) tr...

A highly visible reminder about the gastrointestinal dangers of today's nonsteroidal anti-inflammatory drugs #NSAIDs -- ...
05/26/2021
Ibuprofen and ulcers: What Rep. Debbie Dingell’s emergency surgery can teach us

A highly visible reminder about the gastrointestinal dangers of today's nonsteroidal anti-inflammatory drugs #NSAIDs -- Rep. Debbie Dingell, member of the U.S. House of Representatives, develops a perforated ulcer and undergoes emergency surgery washingtonpost.com/lifestyle/wellness/perforated-ulcer-ibuprofen-dingell/2021/05/26/93f18ff8-bcc0-11eb-b26e-53663e6be6ff_story.html

Dingell recently suffered a perforated ulcer, which she and her doctors believe was caused by high doses of Motrin.

Congratulations to our founder and Chief Scientific Officer, Dr. John L. Wallace and his colleagues for their recent pap...
05/20/2021
Effects of Hydrogen Sulfide on the Microbiome: From Toxicity to Therapy

Congratulations to our founder and Chief Scientific Officer, Dr. John L. Wallace and his colleagues for their recent paper detailing how hydrogen sulfide helps resolve inflammation and promote tissue repair in the gastrointestinal tract, particularly with respect to its effect on the #microbiome liebertpub.com/doi/full/10.1089/ars.2021.0004

Antioxidants & Redox Signaling

Congratulations to Don Haut, PhD, member of Antibe's Partnering Advisory Team, for his recent appointment as CEO of Carm...
05/17/2021
Carmine Therapeutics appoints Don Haut as CEO

Congratulations to Don Haut, PhD, member of Antibe's Partnering Advisory Team, for his recent appointment as CEO of Carmine Therapeutics, an emerging leader in gene therapy carminetherapeutics.com/post/carmine-therapeutics-appoints-don-haut-as-ceo

CAMBRIDGE, Mass., May 5, 2021 /PRNewswire/ -- Carmine Therapeutics, Inc., an emerging leader in gene therapy, today announced that Don Haut, PhD has been appointed as its Chief Executive Officer, and member of the Board of Directors. Founded and incubated by EVX Ventures, Carmine is developing next-...

Congratulations to Antibe's Chief Medical Officer,  Dr. Joseph Stauffer, who began a three-day role this morning as Mode...
05/11/2021

Congratulations to Antibe's Chief Medical Officer, Dr. Joseph Stauffer, who began a three-day role this morning as Moderator of the invitation-only, 24th Evolution Summit http://www.s1.evolutionsummit.com. The online Summit features clinical trial opinion leaders discussing drug development topics such as digital innovation, decentralized trials, and patient diversity -- now and in a post-COVID world.

Congratulations to Antibe's Chief Medical Officer, Dr. Joseph Stauffer, who began a three-day role this morning as Moderator of the invitation-only, 24th Evolution Summit http://www.s1.evolutionsummit.com. The online Summit features clinical trial opinion leaders discussing drug development topics such as digital innovation, decentralized trials, and patient diversity -- now and in a post-COVID world.

We've announced an agreement to amalgamate Antibe Therapeutics Inc. and Antibe Holdings Inc. This agreement follows nego...
05/07/2021
Antibe Therapeutics Announces Agreement to Unify Intellectual Property Ownership – Antibe

We've announced an agreement to amalgamate Antibe Therapeutics Inc. and Antibe Holdings Inc. This agreement follows negotiations originally announced in December 2020.

“This is a desirable outcome for all parties,” commented Dan Legault, Antibe Therapeutics' CEO. “With this agreement, we’ve unlocked value by providing potential partners and institutional investors with a straightforward, unified IP base for our drugs and platform. We’ve also extinguished a significant royalty commitment, amounting to 15% of licensing revenues from our pipeline drugs. As we accelerate our partnering efforts for the large markets, we expect this agreement to strengthen our position and expand our options for monetization.”

antibethera.com/news/antibe-therapeutics-announces-agreement-to-unify-intellectual-property-ownership

– Amalgamation secures 100% ownership of IP underlying Antibe’s pipeline – Strengthens position in large-market partnering discussions TORONTO, CANADA — (May 7, 2021) – Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF) (“Antibe” or the “Company”), a clinical stage company leveragin...

Did you know that 65% of U.S. patients with #osteoarthritis are prescribed NSAIDs? That more than half of patients with ...
05/04/2021

Did you know that 65% of U.S. patients with #osteoarthritis are prescribed NSAIDs? That more than half of patients with knee osteoarthritis are younger than 65? These facts and much more in the Arthritis Foundation's 2020 Arthritis by the Numbers arthritis.org/getmedia/73a9f02d-7f91-4084-91c3-0ed0b11c5814/ABTN-2020-FINAL.pdf

Did you know that 65% of U.S. patients with #osteoarthritis are prescribed NSAIDs? That more than half of patients with knee osteoarthritis are younger than 65? These facts and much more in the Arthritis Foundation's 2020 Arthritis by the Numbers arthritis.org/getmedia/73a9f02d-7f91-4084-91c3-0ed0b11c5814/ABTN-2020-FINAL.pdf

Have you met our Partnering Advisory Team? antibethera.com/about-us/partnering-advisory-team
04/29/2021

Have you met our Partnering Advisory Team? antibethera.com/about-us/partnering-advisory-team

Have you met our Partnering Advisory Team? antibethera.com/about-us/partnering-advisory-team

The unique properties of hydrogen sulfide underlie the power of our drug platform -- why hydrogen sulfide? antibethera.c...
04/26/2021

The unique properties of hydrogen sulfide underlie the power of our drug platform -- why hydrogen sulfide? antibethera.com/science/why-h2s

The unique properties of hydrogen sulfide underlie the power of our drug platform -- why hydrogen sulfide? antibethera.com/science/why-h2s

Address

15 Prince Arthur Avenue
Toronto, ON
M5R 1B2

Alerts

Be the first to know and let us send you an email when Antibe Therapeutics posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Antibe Therapeutics:

Our Story

Antibe’s drug pipeline targets large markets in non-addictive pain management. Our lead drug, now in late Phase 2B trials, has demonstrated unprecedented safety in the treatment of chronic pain, a condition that affects hundreds of millions of people worldwide. Our second pipeline drug is designed to replace opioids for post-operative pain, directly addressing a worldwide public health crisis. In the longer term, we will exploit our platform to create drugs that address a range of inflammation-based diseases.

Nearby health & beauty businesses


Other Toronto health & beauty businesses

Show All